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Abstract We evaluated the genetic contribution of the
leukotriene (LT) pathway to risk of coronary artery disease
(CAD) in 4,512 Caucasian and African American subjects
ascertained through elective cardiac evaluation. Of the
three previously associated variants, the shorter “3” and “4”
alleles of a promoter repeat polymorphism in ALOX5
increased risk of CAD in African Americans (OR = 1.4,
95% CI 1.0–1.9; p = 0.04), whereas a haplotype of LTA4H
(HapK) was associated with CAD in Caucasians (OR = 1.2,
95% CI 1.01–1.4; p = 0.03). In Caucasians, Wrst-stage
analysis of 254 haplotype-tagging SNPs in 15 LT pathway
genes with follow-up of 19 variants in stage 2 revealed an
LTA4H SNP (rs2540477) that increased risk of CAD
(OR = 1.2, 95% CI 1.1–1.5; p = 0.003) and a PLA2G4A
SNP (rs12746200) that decreased risk of CAD (OR = 0.7,
95% CI 0.6–0.9; p = 0.0007). The PLA2G4A rs12746200
variant also decreased risk of experiencing a major adverse
cardiac event (MACE = myocardial infarction, stroke, or
death) over 3 years of follow-up (HR = 0.7, 95% CI 0.5–0.9;
p = 0.01), consistent with its cardioprotective eVect. Func-
tional experiments demonstrated that stimulated monocytes
from carriers of LTA4H variants HapK or rs2540477 had
50% (p = 0.002) and 33% (p = 0.03) higher LTB4 produc-
tion, respectively, compared to non-carriers. These ex vivo
results are consistent with LTB4 being the direct product of
the reaction catalyzed by LTA4H and its role in promoting
monocyte chemotaxis to sites of inXammation, including
the artery wall of atherosclerotic lesions. Taken together,
this study provides additional evidence that functional
genetic variation of the LT pathway can mediate athero-
genic processes and the risk of CAD in humans.
Introduction
Class four leukotrienes (LTs) are potent pro-inXammatory
mediators synthesized from arachidonic acid, an omega-6
polyunsaturated fatty acids (PUFAs) (Peters-Golden and
Henderson 2007). The rate-limiting step in this pathway is
catalyzed by the enzyme arachidonic acid 5-lipoxygenase
(ALOX5). The biologically active LTs are synthesized by
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subsequent conversion to LTB4 and the cysteinyl LTs
(LTC4, LTD4, and LTE4) via enzymatic reactions by LTA4
hydrolase (LTA4H) and LTC4 synthase (LTC4S), respec-
tively (Peters-Golden and Henderson 2007). LTs then aVect
the function of target cells, including monocytes and other
pro-inXammatory leukocytes, through receptor-mediated
signal transduction.
While LTs have long been known to be involved in
chronic allergic inXammatory conditions, such as asthma,
the LT pathway has also recently garnered attention for its
potential role in coronary artery disease (CAD)-related
traits. This stems from a series of biochemical, genetic, and
pharmacological studies over the last few years that have
provided evidence for the pro-atherogenic role of LTs
(Back and Hansson 2006; Mehrabian and Allayee 2003;
Tymchuk et al. 2006). For example, genetic deWciency for
ALOX5 in mice protects against aortic lesion formation and
leads to other metabolic disturbances (Mehrabian et al.
2002, 2005, 2008). Other mouse studies have reported the
involvement of LT pathway genes in atherosclerosis-
related traits as well, including the LT receptors and
ALOX5 activating protein (ALOX5AP) (Ahluwalia et al.
2007; Aiello et al. 2002; Heller et al. 2005; Jawien et al.
2006, 2008; Subbarao et al. 2004).
Studies in humans have also provided evidence supporting
the notion that LTs participate in atherosclerotic processes.
Immunohistochemical studies have shown that ALOX5,
ALOX5AP, and LTA4H are abundantly expressed in arterial
walls of CAD patients, with ALOX5 having markedly
increased expression in advanced lesions and localizing to
macrophages, dendritic cells, and neutrophilic granulocytes
(Qiu et al. 2006; Spanbroek et al. 2003). In addition, indi-
viduals carrying the shorter alleles of a functional ALOX5
promoter polymorphism, consisting of tandem Sp1 binding
sites, have signiWcantly increased carotid atherosclerosis
and risk of myocardial infarction (MI), particularly in the
context of high dietary arachidonic acid levels (Allayee
et al. 2008; Dwyer et al. 2004). This is supported by studies
that have reported associations between other ALOX5 and
ALOX5AP variants with CAD-related phenotypes (Burdon
et al. 2010; Carlson et al. 2007; Crosslin et al. 2009; Helga-
dottir et al. 2004). More recently, a 10-SNP haplotype of
LTA4H, designated HapK, has been associated with MI in
Caucasians and African Americans, with a more pro-
nounced eVect in the latter group (Helgadottir et al. 2006),
and LTC4S variants have been associated with surrogate
measures of CAD, including coronary artery calciWcation
and carotid atherosclerosis (Iovannisci et al. 2007). Impor-
tantly, these genetic studies are bolstered by functional data
showing that the associated variants/haplotypes lead to
increased gene expression or LT production (Allayee et al.
2008; Helgadottir et al. 2004,  2006; Sanak et al. 2000;
Vikman et al. 2009). Despite these reports, evidence for
association of LT pathway genes with CAD traits has not
been consistently observed across all studies (Assimes et al.
2008; Koch et al. 2007; Zee et al. 2006; Zintzaras et al.
2009). Thus, the aim of the present study was to compre-
hensively evaluate the genetic contribution of the LT path-
way to CAD in a large cohort of subjects undergoing
elective cardiac evaluation.
Materials and methods
Study subjects
GeneBank is a single site (Cleveland Clinic) sample repository
generated from patients undergoing elective diagnostic
coronary angiography or elective cardiac computed tomo-
graphic angiography with extensive clinical and laboratory
characterization and longitudinal observation (Bhatta-
charyya et al. 2008; Nicholls et al. 2010). Ethnicity was
self-reported and information regarding demographics,
medical history, and medication use was obtained by
patient interviews and conWrmed by chart reviews. All
clinical outcome data were veriWed by source documentation.
CAD was deWned as adjudicated diagnoses of stable or
unstable angina, MI (adjudicated deWnition based on deW-
ned electrocardiographic changes or elevated cardiac
enzymes), angiographic evidence of ¸50% stenosis of one
or more major epicardial vessel, and/or a history of known
CAD (documented MI, CAD, or history of revasculariza-
tion). Prospective cardiovascular risk was assessed by the
incidence of major adverse cardiac events (MACE) during
3 years of follow-up from the time of enrollment, which
included nonfatal MI, nonfatal stroke, and all-cause mortal-
ity. Nonfatal events were deWned as MI or stroke in patients
who survived at least 48 h following the onset of symp-
toms. Adjudicated outcomes ascertained over the ensuing
3 years for all subjects following enrollment were
conWrmed using source documentation. All patients pro-
vided written informed consent prior to being enrolled in
GeneBank and the study was approved by the Institutional
Review Board of the Cleveland Clinic. The present genetics
study was approved by the Institutional Review Boards of
the Cleveland Clinic and USC Keck School of Medicine.
Clinical laboratory measurements
Samples were collected from overnight fasted subjects on
the day of elective cardiac catheterization. Plasma aliquots
were isolated from whole blood collected into EDTA tubes,
maintained at 0–4°C immediately following phlebotomy,
processed within 4 h of blood draw, and stored at ¡80°C
until analysis. Plasma levels of total cholesterol, low-den-
sity lipoproteins (LDL), high-density lipoproteins (HDL),Hum Genet (2011) 129:617–627 619
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triglycerides, and high sensitivity C-reactive protein (CRP)
were measured on the Abbott ARCHITECT platform
(Abbott Diagnostics, Abbott Park IL).
Genotyping
Genomic DNA was extracted from isolated buVy coats
using DNeasy isolation kits (Qiagen, Valencia, CA). Geno-
typing of the 274 haplotype-tagging SNPs was carried out
using the Illumina GoldenGate System, which involves
using allele-speciWc primer extension in combination with
multiplex PCR with universal primers. Technical details
regarding this methodology are available from Illumina,
Inc. (http://www.illumina.com). Haplotype-tagging SNPs
were selected using the HapMap data for Caucasians and
the Tagger program (de Bakker et al. 2005). Genotyping of
previously associated SNPs/variants and those selected for
replication in stage 2 was performed using either fragment
analysis, as described elsewhere (Dwyer et al. 2004), or the
TaqMan Allelic Discrimination system from Applied
Biosystems, Inc. (Foster City, CA) (Livak 1999, 2003). For
determination of HapA and HapK, we genotyped the same
SNPs as reported by deCode Genetics (Helgadottir et al. 2004,
2006), which were rs17222814, rs10507391, rs4769874, and
rs9551963 for HapA and rs61937881 (SG12S16), rs2660880,
rs6538697, rs1978331, rs17677715, rs2247570, rs2660898,
rs2540482, rs2660845, and rs2540475 for HapK (Supple-
mental Table 1).
Statistical analyses
Prior to analysis, all variants were tested for Hardy–Weinberg
equilibrium in subjects without CAD using a 2 test. SNPs
deviating from HWE (p < 0.05) were excluded from further
analysis. Haplotypes of ALOX5AP (HapA) and LTA4H
(HapK) were estimated using an expectation-maximization
(EM) algorithm to generate maximum likelihood estimates
of haplotype frequencies, which assigns the probability that
each individual possesses a particular haplotype pair.
Unconditional multiple logistic regression was used to
independently test for association with CAD with adjust-
ment for age and sex under dominant genetic models (as a
means to increase sample size and power). The fully
adjusted regression models included age, sex, medication
use, plasma CRP levels, alcohol consumption, and Fra-
mingham ATP-III risk score (which includes smoking and
diabetes status) and the results are reported as odds ratios
(OR) with 95% conWdence intervals (CI). Since we were
testing speciWc hypotheses with respect to the HapA and
HapK haplotypes of ALOX5AP and LTA4H, respectively,
these analyses were performed as tests of a single haplotype
compared to all other haplotypes (i.e., carriers of HapA or
HapK vs. non-carriers). For analyses of HapK, we also
performed a haplotype score test with all haplotypes having
frequencies greater than 1%, as implemented in the
Haplo.Stats package. All analyses were performed using
SAS version 9.2 (SAS Institute Inc, Cary, NC) or R 2.10.1
(http://www.R-project.org) and carried out separately in
Caucasian and African American subjects.
Kaplan–Meier failure estimates were plotted to illustrate
diVerences in rates for developing a MACE over 3 years of
follow-up as a function of genotype. Subjects experiencing
a MACE within 14 days of enrollment were excluded. Due
to sample size limitations, we assumed dominant genetic
models and signiWcance was assessed using a log-rank test.
Relative risk for experiencing a MACE was assessed using
Cox proportional hazard models with adjustment for age,
sex, medication use, plasma CRP levels, alcohol consump-
tion, and Framingham ATP-III risk score (which includes
diabetes status). Other variables tested, but not included in
the Wnal model, were BMI and smoking. Adjusted hazard
ratio (HR) and 95% CI are reported with 2-sided p values
that were considered signiWcant when <0.05. Time-to-event
analyses were carried out using Stata 8.2 (StataCorp LP,
College Station, TX).
Monocyte samples for functional studies
Monocyte samples for the functional analysis of genetic
variants came from the baseline visit of a randomized,
double blind, placebo-controlled intervention trial to
examine the eVect of omega-3 fatty acid supplementation
in subjects with diVerent ALOX5 promoter variants. The
registry number for this study is NCT00536185 and
details of the study design can be found at the ClinicalTri-
als.gov website. Healthy adults between 20 and 59 years
of age who had not been diagnosed with any major disor-
der and who self-identiWed as African American, Black,
or a person of African descent, were recruited into the
study from three study sites in Davis, Sacramento, and
Oakland, California. Potential study participants received
a brief interview to characterize general health, previous
diagnosis of major diseases, smoking and alcohol usage,
medication, nutritional supplements, and other factors.
Eligible subjects that had one of the six 5-LO promoter
repeat genotypes of interest (33, 34, 44, 35, 45, 55) were
subsequently invited to participate in the study. A fasting
blood sample was used for a complete blood count, lipid
and chemistry panel analysis to identify any undiagnosed
medical problems. Study participants that had a physi-
cian-diagnosed chronic inXammatory disease (arthritis,
autoimmune disease, or asthma), CVD, hypertension,
diabetes, or a lipid disorder that required regular use of
anti-inXammatory or lipid-lowering medication were
excluded. Subjects with abnormal results on standard
chemistry and lipid panels or a complete blood count that620 Hum Genet (2011) 129:617–627
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suggested underlying undiagnosed disease were also
excluded and referred to their physician for further evalu-
ation. The institutional review boards of The University
of California, Davis, Alta Bates Summit Medical Center,
the USC Keck School of Medicine reviewed and
approved ethical permission for all procedures involving
human volunteers and the protocols. Written informed
consent was obtained from all study participants.
Cell isolations
At the baseline visit subsequent to enrollment, a fasting
blood sample (80 ml) from each participant was collected
into heparinized tubes and processed within 4 h. Plasma
was separated after low-speed centrifugation and the buVy
coat containing mononuclear cells (lymphocytes and mono-
cytes) and granulocytes was then removed and diluted
with approximately one volume of Hank’s Balanced Salt
Solution (HBSS) into a total volume of approximately
32 ml. Monocytes were puriWed using two-step gradients
and washed once with HBSS, followed by positive selec-
tion using CD14-labeled magnetic microbeads with an LS
magnetic column (Miltenyi Biotec, Auburn, CA), as
described previously (Vikman et al. 2009). Purity of mono-
cytes was assessed by FACS analysis (BD FACSCalibur)
using PE-labeled anti-CD14 antibody (Miltenyi Biotec) and
an isotype control reagent (IgG2a; BD Biosciences, San
Jose, CA). The median percent purity (25th/75th percen-
tiles) of monocytes was 93% (89%/96%). SNP genotyping
was carried out as described above.
Real-time RNA quantitation
Total RNA was isolated using RNeasy kits from Qiagen,
Inc. (Valencia, CA) of which 1 g was reverse transcribed
using cDNA Archive kits from ABI (Foster City, CA).
Real-time mRNA levels for LTA4H and beta-glucuroni-
dase (GUSB) as an endogenous control were determined
in triplicate using pre-developed assays (LTA4H,
Hs00168505_m1; GUSB, Hs99999908_m1) from Applied
Biosystems Inc. (Foster City, CA). LTA4H mRNA levels
were normalized to those of GUSB and the replicates were
averaged to determine transcript abundance in each sample
relative to a reference sample. The mRNA levels of GUSB,
as determined by the average Ct values for the triplicate
reactions, did not diVer across LTA4H genotypes in these
monocyte samples.
Ex vivo LTB4 production analyses
Within 1 h after isolation from blood, monocytes (1 £ 106/
ml) were cultured at 37°C in 5% CO2 using RPM1 1640
complete media supplemented with 10% heat-inactivated
autologous plasma. The cells were then stimulated with
either the calcium ionophore A23187 (Sigma, St. Louis,
MO) at a Wnal concentration of 10 M or with DMSO as a
control culture. After a 60-min incubation, the supernatants
and cell pellets were collected and the supernatants were
extracted using 60 mg HLB solid phase extraction
cartridges (Waters, Inc; Milford, MA). Oxylipid analytes,
including LTB4, were chromatographically separated on an
ultra-performance liquid chromatography system equipped
with a 2.1 £ 150 mm Acquity BEHC18 reversed phase
column and quantiWed by negative mode electrospray ioni-
zation on a Quattro Micro tandem mass spectrometer
(Waters, Inc.). One in 20 samples was analyzed in replicate
to assess analytical precision. DiVerences in mRNA and
LTB4 levels were determined using t tests (Statview
version. 5.0; SAS Institute Inc., Cary, NC) with p values
<0.05 considered as statistically signiWcant.
Results
Clinical characteristics of GeneBank subjects
The general characteristics of the Caucasian and African
American GeneBank subjects used in the present study are
presented in Table 1. For both ethnicities, subjects with
CAD at baseline exhibited the known traditional risk
factors for cardiovascular disease, including being older,
more likely to be male, and having higher plasma levels of
triglycerides and CRP and lower HDL-cholesterol levels
(Table 1). However, plasma total and LDL-cholesterol lev-
els were lower in subjects with CAD, which is likely due to
these patients having a higher prevalence of co-morbidities
and taking lipid-lowering medications.
Evaluation of previously reported LT pathway variants
Table 2 lists the LT pathway genes selected for the present
study and their biological functions. We Wrst evaluated
several variants of ALOX5,  ALOX5AP, and LTA4H that
were previously associated with CAD-related phenotypes
(Dwyer et al. 2004; Helgadottir et al. 2004, 2006) in 3,747
Caucasian and 765 African American subjects from the
GeneBank cohort. These included a variable number of
tandem Sp1 repeats in the ALOX5 promoter as well as hap-
lotypes of ALOX5AP (HapA) and LTA4H (HapK) (Supple-
mental Table 1). As in our prior analyses of the ALOX5
repeats (Allayee et al. 2008), carriers of the functional
“short” promoter alleles with “3” and “4” Sp1 repeats (i.e.
genotypes of 3/3,3/4,4/4,3/5,4/5,3/6,3/7,4/6,4/8) were com-
pared with subjects carrying alleles of ¸“5” repeats (i.e.
genotypes of 5/5,5/6,5/7,5/8,5/9,6/6,6/7). In the overall
GeneBank cohort, the frequencies of the “3” and “4”Hum Genet (2011) 129:617–627 621
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repeats were »1 and 14%, respectively, in Caucasians and
30 and 14%, respectively, in African Americans, which are
consistent with previous reports for these ethnicities
(Assimes et al. 2008; Dwyer et al. 2004; Lima et al. 2006).
In Caucasians, there was no association of the “3” and “4”
alleles with CAD (Table 3), whereas African American car-
riers of these shorter repeats had increased risk compared to
non-carriers (OR = 1.4; 95% CI 1.01–1.9; p = 0.04). Analy-
ses of the ALOX5AP and LTA4H haplotypes, adjusted for
age and sex, yielded signiWcant evidence of association
with HapK and CAD in Caucasians (OR = 1.2; 95% CI
1.01–1.4; p = 0.03) but not with HapA (Table 3). Further
adjustment for CRP levels, medication use, alcohol
consumption, and Framingham risk score, which includes
diabetes and smoking status slightly attenuated these results
but still yielded a signiWcant p value of 0.05 for HapK. An
analysis using a haplotype score test that included all possi-
ble LTA4H haplotypes having frequencies greater than 1%
(n = 13) also yielded consistent evidence for association
with only HapK (p = 0.07). By comparison, neither haplo-
type was associated with CAD in African Americans.
Two-stage analysis of LT pathway genes with
haplotype-tagging SNPs
In order to comprehensively evaluate the contribution of
LT pathway genes to CAD in an unbiased fashion, we next
carried out a two-stage association study in Caucasian sub-
jects. In the Wrst stage, we used HapMap data for individu-
als of European ancestry (to match GeneBank) and the
Tagger program to identify haplotype-tagging SNPs in 15
pathway genes that play important roles in LT biosynthesis,
signaling, and degradation (Table 2). For this purpose, we
chose an r2 of 0.9 between SNPs and included the genomic
region spanning 10 kb upstream and 5 kb downstream of
each gene to capture potential regulatory elements. These
criteria resulted in the selection of 274 haplotype-tagging
Table 1 General characteristics of the GeneBank participants
Data are shown as mean § SD with the exception of CRP levels which are shown as median (IQR). Two-sided p values are reported between sub-
jects with and without CAD at baseline
Caucasian African American
Without CAD 
(n =9 1 3 )
With CAD 
(n =2 , 8 3 4 )
p value Without CAD 
(n =2 6 3 )
With CAD 
(n =5 0 2 )
p value
Age (years) 59 § 12 66 § 11 <0.0001 57 § 11 61 § 11 <0.0001
Male/female (n) 478/435 2,140/694 <0.0001 99/164 264/238 <0.0001
BMI (kg/m2) 29.7 § 6.8 29.4 § 5.6 0.92 33.6 § 8.1 31.2 § 7.1 <0.0001
Total cholesterol (mg/dl) 177 § 37 168 § 40 <0.0001 182 § 38 176 § 50 0.01
HDL-cholesterol (mg/dl) 42 § 13 37 § 11 <0.0001 51 § 15 46 § 15 <0.0001
LDL-cholesterol (mg/dl) 108 § 31 100 § 33 <0.0001 111 § 72 106 § 43 0.13
Triglycerides (mg/dl) 129 § 81 155 § 105 <0.0001 123 § 81 128 § 83 0.32
CRP (mg/l) 2.2 (3.4) 3.1 (5.7) <0.0001 2.2 (3.7) 3.0 (5.6) 0.008
DBP (mmHg) 75 § 12 74 § 12 0.004 81 § 13 77 § 13 0.0002
SBP (mmHg) 133 § 20 135 § 21 0.003 139 § 22 140 § 23 0.53
Table 2 The major genes of LT biosynthetic pathway and their
function
Gene (symbol) Function
Cytosolic phospholipase A2 
group 4A (PLA2G4A)
Releases arachidonic acid from 
cell membranes
Cytosolic phospholipase A2 
group 5 (PLA2G5)
Releases arachidonic acid from 
cell membranes
Arachidonic acid 
5-lipoxygenase (ALOX5)
Incorporates oxygen into 
arachidonic acid and forms LTA4
ALOX5 activating protein 
(ALOX5AP)
Presents arachidonic acid to 
and activates ALOX5
LTA4 epoxide hydrolase 
(LTA4H)
Converts LTA4 to LTB4
LTC4 synthase (LTC4S) Converts LTA4 to the Wrst 
cysteinyl LT, LTC4
LTB4 receptor 1 (LTB4R) Receptor for LTB4
LTB4 receptor 2 (LTB4R2) A second receptor for LTB4
Cysteinyl leukotriene 
receptor 1 (CysLTR1)
Receptor for cysteinyl LTs 
(LTC4, LTD4, and LTE4)
Cysteinyl leukotriene 
receptor 2 (CysLTR2)
A second receptor for the 
cysteinyl LTs
Microsomal glutathione 
S-transferase 1 (MGST1)
Cysteinyl LT metabolism
Microsomal glutathione 
S-transferase 2 (MGST2)
Cysteinyl LT metabolism
Microsomal glutathione 
S-transferase 3 (MGST3)
Cysteinyl LT metabolism
Prostaglandin reductase 
1 isoform 1 (PTGR1)
Catalyzes degradation of LTB4
Cytochrome P450 4F3 
(CYP4F3)
Catalyzes degradation of LTB4622 Hum Genet (2011) 129:617–627
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SNPs (listed in Supplemental Table 1), of which 254 were
successfully genotyped in stage 1. This dataset included
1,000 sequential GeneBank patients, comprised of 804 and
196 subjects with and without CAD, respectively. In order
to obtain a more balanced “case–control” dataset for stage
1, we also included an additional 322 “control” subjects
without CAD that were selected from GeneBank.
Based on our two-stage study design, we chose an unad-
justed p value of <0.05 as the threshold for suggestive evi-
dence of association in the stage 1 analyses. After
adjustment for age and sex, 19 SNPs in the ALOX5,
ALOX5AP,  LTA4H,  CYP4F3,  MGST1,  MGST2,  MGST3,
and  PLA2G4A genes demonstrated nominal evidence of
association (Supplemental Table 2). In stage 2, we geno-
typed these 19 SNPs in 2,425 additional Caucasian subjects
(395 without CAD/2030 with CAD) and obtained evidence
of association with one variant in PLA2G4A (rs12746200;
p = 0.03) and another in LTA4H (rs2540477; p = 0.01)
(Table 4). The direction of the associations for these two
SNPs was consistent in both stages and became even more
Table 3 Association of previously reported LT pathway variants in Caucasian and African American GeneBank subjects
Sample sizes are shown based on complete genotype and phenotype data for each variant
OR (95% CI) odds ratio (95% conWdence intervals)
* p values were obtained from a logistic regression with adjustment for age and gender
a Combined frequencies of the “3” and “4” repeat alleles are given; non-carriers = genotypes of 5/5, 5/6, 5/7, 5/8, 5/9, 6/6, 6/7; carriers = genotypes
of 3/3, 3/4, 4/4, 3/5, 4/5, 3/6, 3/7, 4/6, 4/8
b HapA = GTGA derived from SNPs rs17222814 (G), rs10507391 (T), rs4769874 (G), rs9551963 (A)
c HapK = CGTATTTCGG derived from SNPs rs61937881 (SG12S16) (C), rs2660880 (G), rs6538697 (T), rs1978331 (A), rs17677715 (T),
rs2247570 (T), rs2660898 (T), rs2540482 (C), rs2660845 (G), rs2540475 (G)
SNP/variant (gene) Risk allele/haplotype frequency OR (95% CI)
Without CAD (n) With CAD (n) Non-carriers Carriers p value*
Caucasian
Promoter repeats (ALOX5)a 0.15 (886) 0.17 (2,736) 1.0 1.1 (1.0–1.4) 0.2
HapA (ALOX5AP)b 0.15 (913) 0.15 (2,834) 1.0 1.1 (0.9–1.3) 0.3
HapK (LTA4H)c 0.14 (912) 0.16 (2,830) 1.0 1.2 (1.01–1.4) 0.03
African American
Promoter repeats (ALOX5)a 0.43 (261) 0.48 (495) 1.0 1.4 (1.01–1.9) 0.04
HapA (ALOX5AP)b 0.06 (263) 0.06 (502) 1.0 1.1 (0.7–1.6) 0.8
HapK (LTA4H)c 0.05 (263) 0.06 (502) 1.0 0.9 (0.5–1.4) 0.5
Table 4 Association of PLA2G4A and LTA4H SNPs with CAD in the two-stage analysis
Sample sizes are shown based on complete genotype and phenotype data for each variant
MAF minor allele frequency, OR (95% CI) odds ratio (95% conWdence intervals)
* p values were obtained from a logistic regression with adjustment for age and gender
SNP (gene) MAF OR (95% CI)
rs12746200 (PLA2G4A) Without CAD (n) With CAD (n)A AA G / G G p value*
Stage 1 0.11 (516) 0.10 (802) 1.0 0.8 (0.6–1.0) 0.05
Stage 2 0.11 (390) 0.08 (1,982) 1.0 0.6 (0.5–0.9) 0.03
Combined 0.11 (906) 0.09 (2,784) 1.0 0.7 (0.6–0.9) 0.0007
SNP (gene) MAF OR (95% CI)
rs2540477 (LTA4H) Without CAD (n) With CAD (n) TT TC/CC p value*
Stage 1 0.22 (515) 0.26 (803) 1.0 1.3 (1.0–1.7) 0.02
Stage 2 0.20 (382) 0.25 (1,980) 1.0 1.4 (1.1–1.7) 0.02
Combined 0.21 (897) 0.25 (2,783) 1.0 1.3 (1.1–1.5) 0.003
HapK non-carriers 0.08 (663) 0.11 (1,973) 1.0 1.3 (1.1–1.8) 0.01
HapK carriers 0.57 (234) 0.60 (810) 1.0 1.7 (0.6–5.0) 0.34Hum Genet (2011) 129:617–627 623
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signiWcant in a combined analysis with all subjects
(Table 4). Of note, rs12746200 had a protective eVect
(OR = 0.7; 95% CI 0.6–0.9; p = 0.0007), whereas rs2540477
increased risk of CAD (OR = 1.2; 95% CI 1.1–1.5;
p = 0.003). After full adjustment for the same covariates
described above, the p values for the association of
PLA2G4A rs12746200 and LTA4H rs2540477 with CAD
became 0.0014 and 0.005, respectively. In the GeneBank
subjects, rs2540477 was in strong linkage disequilibrium
with one of the SNPs that is part of HapK (rs2540482;
r2 = 0.86), raising the possibility that the association we
observed with rs2540477 was due to its linkage with HapK.
Therefore, we performed a stratiWed analysis and observed
signiWcant association of rs2540477 with CAD even in sub-
jects who did not carry HapK (Table 4). By comparison, a
haplotype of HapK that included the rare allele of
rs2540477 was not associated with increased risk of CAD,
which could have been due to decreased sample size
(Table 4).
Prospective analysis with major adverse cardiac events 
(MACE)
We next determined whether PLA2G4A rs12746200 and
LTA4H rs2540477 were also associated with risk of future
MACE (MI, stroke, or death) over 3 years of follow-up.
Consistent with the results of the cross-sectional analysis,
AG/GG carriers of rs12746200 had fewer numbers of
MACE compared to the AA genotype group (Fig. 1a; log-
rank p = 0.03), with an adjusted HR of 0.7 (95% CI = 0.5–
0.9; p = 0.01; Table 5). By comparison, rs2540477 did not
aVect risk of future MACE (Fig. 1b; Table 5) and stratify-
ing these analyses by HapK did not alter the results (data
not shown).
Functional characterization of associated variants
To investigate functional diVerences between the associ-
ated PLA2G4A and LTA4H variants, we used monocytes
isolated from 105 healthy African Americans who had par-
ticipated in a previous clinical intervention study to exam-
ine the eVects of omega-3 fatty acid supplementation in
subjects with diVerent  ALOX5 promoter variants (see
“Materials and methods”). Only monocytes from the base-
line visit were used for this purpose. We Wrst performed
real-time gene expression experiments, in reference to beta-
glucuronidase (GUSB) as an endogenous control, which did
not reveal signiWcant diVerences in LTA4H mRNA levels
between carriers of either LTA4H rs2540477 or HapK
(Fig. 2a). However, ex vivo LTB4 production in response
to stimulation with the calcium ionophore A23187 was
signiWcantly higher by approximately 50% in monocytes
from subjects carrying HapK compared to non-carriers
(9.2 § 3.8 vs. 5.9 § 3.3 nmol/L; p = 0.002) (Fig. 2b). Simi-
larly, TC/CC carriers of rs2540477 had 33% increased
LTB4 production compared to TT subjects (7.5 § 3.6 vs.
Table 5 Risk of prospective MACE in relation to PLA2G4A and
LTA4H variants
Sample sizes are shown based on complete genotype and phenotype
data for each variant
* Hazard ratios (HRs) were calculated only in Caucasians with adjust-
ment for age, sex, medication use (statins and/or aspirin), plasma CRP
levels, alcohol consumption, and Framingham ATP-III risk score
rs12746200 (PLA2G4A) AA 
(n = 2,943)
AG/GG 
(n = 589)
p value*
Number of events (%) 404 (14) 61 (10) 0.03
Adjusted HR (95% CI)* 1.0 0.7 (0.5–0.9) 0.01
rs2540477 (LTA4H)T T  
(n =2 , 0 9 5 )
TC/CC 
(n = 1,435)
p value*
Number of events (%) 269 (14) 193 (13) 0.57
Adjusted HR (95% CI)* 1.0 1.1 (0.8–1.3) 0.59
Fig. 1 Relationship between LT pathway variants and incident risk of
MACE. a Kaplan–Meier survival analyses demonstrating that carriers
(AG/GG) of PLA2G4A variant rs12746200 have signiWcantly lower a
rate of MACE over three years of follow-up (p = 0.03). b There is no
diVerence in the rate of MACE between carriers and non-carriers of
the LTA4H variant rs2540477. MACE were deWned as the occurrence
of MI, stroke, or all-cause mortality over 3 years of follow-up from the
time of enrollment624 Hum Genet (2011) 129:617–627
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5.9 § 3.3 nmol/L;  p =0 . 0 3 )  ( F i g .2b). By comparison,
LTB4 production in control cultures of monocytes incu-
bated with DMSO was very low and not signiWcantly diVer-
ent between carriers and non-carriers of either HapK
(0.42 § 0.40 vs. 0.76 § 1.3 nmol/L, respectively; p = 0.39)
or rs2540477 (0.58 § 0.82 vs. 0.76 § 1.4 nmol/L, respec-
tively;  p = 0.55). In addition, since these subjects were
recruited based on carrying diVerent ALOX5 promoter alle-
les, we also stratiWed the analyses of LTA4H mRNA
expression and LTB4 production by ALOX5 genotype.
However, this did not alter the results with rs2540477 and
HapK (data not shown). Since only two subjects carried the
rare allele of rs12746200, we were not able to determine
whether this PLA2G4A variant aVected mRNA and/or LT
production in these monocyte samples.
Discussion
In the present study, we carried out a comprehensive
genetic analysis of the LT pathway in a relatively large
cohort of subjects ascertained through elective cardiac eval-
uation. Of the 15 genes studied, our results provide
evidence for the contributions of ALOX5,  LTA4H, and
PLA2G4A to risk of CAD. Two newly discovered SNPs in
LTA4H and PLA2G4A were identiWed using an unbiased
two-stage study design with dense haplotype-tagging SNPs.
While the association of LTA4H rs2540477 with prevalent
CAD may have been due to linkage disequilibrium between
this variant and HapK, we also observed an independent
eVect in subjects who did not carry HapK. These results
suggest that multiple susceptibility alleles of LTA4H may
exist in the population that increase the risk of CAD. By
comparison, the rs12746200 variant of PLA2G4A was
cardioprotective, decreasing both the likelihood of having
CAD and the risk for experiencing a future MACE over
3 years of follow-up. Thus, the results from these cross-
sectional and longitudinal analyses provide consistent evidence
for a protective eVect of this PLA2G4A variant. These latter
Wndings are also novel since, to our knowledge, PLA2G4A
was not evaluated in previous genetic studies of the LT
pathway (Bevan et al. 2008; Burdon et al. 2010; Crosslin
et al. 2009).
Our results also corroborate previously reported associa-
tions of CAD-related phenotypes with an ALOX5 promoter
polymorphism (Allayee et al. 2008; Dwyer et al. 2004) and
HapK in LTA4H (Crosslin et al. 2009; Helgadottir et al.
2006). In this regard, the shorter ALOX5 “3” and “4”
promoter repeats, which lead to increased ALOX5 expres-
sion (Allayee et al. 2008; Vikman et al. 2009), were only
associated with CAD in African Americans. One possibility
for this observation may be due to the tenfold higher fre-
quency of the “3” allele in African Americans compared to
Caucasians (»30 vs. 1–2%). However, it should also be
noted that the “3” and “4” repeats may not contribute
appreciably to CAD and/or MI in Caucasians, as has been
reported by other groups (Gonzalez et al. 2007; Maznyczka
et al. 2008). Conversely, we observed association of HapK
in Caucasians but not African Americans, which may have
been due to the relatively fewer African Americans subjects
in our study population. Interestingly, HapK is rare in
subjects from the African continent and its presence in
African Americans has been suggested to be a consequence
of admixture with individuals of European descent (Helga-
dottir et al. 2006). Since HapK was previously associated
more strongly with MI in African Americans than in Cau-
casians, this raises the question of whether HapK interacts
with other genetic variants that are speciWc to or more fre-
quent in subjects of African ancestry. As discussed above,
one such variant could be the “3” repeat allele of the
Fig. 2 EVect of LTA4H variants on gene expression and ex vivo LTB4
production. a LTA4H mRNA levels in monocytes are not signiWcantly
diVerent between carriers and non-carriers of the HapK or rs2540477
variants. Real-time PCR was carried out in triplicate and expression
levels were normalized to GUSB as an endogenous control.
b Monocytes isolated from carriers of HapK or rs2540477 produce
signiWcantly higher levels of LTB4 than non-carriers. Monocytes were
isolated from healthy subjects and stimulated with the calcium
ionophore A23187 for 60 min. LTB4 was measured in the supernatant
by negative mode electrospray ionization tandem mass spectrometry.
Data are shown as mean § SE and the number of samples analyzed for
each genotype is given in parenthesesHum Genet (2011) 129:617–627 625
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ALOX5 promoter and could be addressed in studies of
larger African American cohorts. In this regard, it should be
noted that we did not adjust for population admixture in this
African American sample, which could also potentially
confound the results of association studies. Lastly, we did
not observe association of ALOX5AP HapA with CAD risk
in either African Americans or Caucasians. The genetic
contribution of HapA to cardiovascular phenotypes is not
entirely clear since attempts to replicate its association have
yielded both positive (Helgadottir et al. 2005; Shah et al.
2008) and negative (Koch et al. 2007; Lemaitre et al. 2009;
Linsel-Nitschke et al. 2008; Tsai et al. 2009; Zee et al.
2006; Zintzaras et al. 2009) results.
Another important aspect of our study is the ex vivo
functional experiments demonstrating increased LTB4 pro-
duction in stimulated monocytes from subjects carrying
HapK or rs2540477. These results provide a biologically
plausible mechanism for the increased risk of CAD con-
ferred by these LTA4H variants since LTB4 is a direct prod-
uct of the reaction catalyzed by this enzyme and is a potent
chemotactic molecule that mediates the recruitment of neu-
trophils, monocytes, and other leukocytes to sites of inXam-
mation, including the arterial wall of atherosclerotic
lesions. Moreover, LTB4-mediated activation of leukocytes
can induce myeloperoxidase release and further contribute
to the progression of atherosclerosis (Nicholls and Hazen
2005; Samuelsson 1983). Presumably, rs2540477 or the
SNPs comprising HapK are not the underlying causal
variant(s) since they are located in the non-coding regions
of  LTA4H and, based on our results, do not aVect gene
expression. In depth sequencing of LTA4H-coding regions
in subjects carrying HapK or rs2540477 may help to iden-
tify putative amino acid substitutions that are in linkage dis-
equilibrium with these variants and/or alternatively spliced
isoforms and lead to increased LTB4 production. Addi-
tional studies will be required in order to distinguish
between these possibilities as well as to functionally char-
acterize the PLA2G4A rs12746200 variant.
One limitation of our study was not correcting for multi-
ple comparisons, which raises the possibility that the asso-
ciations we have detected are false positives. Although such
an adjustment would be more appropriate for the two-stage
analyses rather than the speciWc hypotheses we tested with
previously associated variants/haplotypes, this potential
problem is mitigated by the consistency of the results for
rs12746200 and rs2540477 in both stages and in the longi-
tudinal analyses with rs12746200. However, since Gene-
Bank subjects were ascertained through cardiac evaluation
at a tertiary care center, it is still important to conWrm these
associations in independent populations recruited through
other study designs, such as traditional case–control data-
sets. In this regard, it is possible that the contribution of LT
pathway genes to cardiovascular phenotypes are more
readily detectable in the context of dietary PUFAs that
serve as the substrates for LT biosynthesis. Such a concept
would be analogous to our previous studies with ALOX5
and MI (Allayee et al. 2008) and it will be interesting to
determine whether the LTA4H and PLA2G4A variants we
identify herein exhibit nutrigenetic interactions with dietary
PUFAs and CAD as well. Since dietary information was
not collected as part of subject recruitment in GeneBank,
we were not able to carry out such gene–dietary analyses in
this study. Nonetheless, our results provide additional evi-
dence that functional genetic variation in the LT pathway
can modulate atherosclerotic processes and the risk of CAD
in humans.
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